Ibon Garitaonandia | Chief Scientific Officer
CellProthera

Biotech executive with several years of experience advancing stem cell-based therapies from early discovery to clinical translation. Currently Chief Scientific Officer at CellProthera, a French clinical stage biotechnology company developing stem cell-based therapies for ischemic diseases. Completed Phase 2 study in post-acute myocardial infarction and preparing for a pivotal Phase 3 study. Prior to CellProthera, Ibon was CSO at Richmond Research Institute, where I conducted clinical research in cardiovascular indications and CSO at Histocell, where he advanced stem cell-based therapies for spinal cord injury and acute respiratory distress syndrome. Previously, Ibon was Director of Translational Research at International Stem Cell Corporation, where he built preclinical and clinical programs for stem cell-based therapies in traumatic brain injury and Parkinson's disease. Ibon received the world’s first regulatory approval to conduct a human pluripotent stem cell based clinical trial in Parkinson’s disease (NCT02452723). Before that, he was awarded a prestigious California Institute for Regenerative Medicine postdoctoral fellowship to conduct stem cell research at Prof. Jeanne Loring's laboratory at the Center for Regenerative Medicine at the Scripps Research Institute. Ibon received his PhD from the University of Florida and Bachelor's degree from the University of the Basque Country.